The relatively low number of patients with cancer relapse in our cohort precludes any definitive conclusions, although we observe a slight and insignificant trend towards the increased relapse rate when BRAF mutation is considered with reference to LN metastases and extrathyroidal invasion. This evidence concerns the gene BRAF and cancer.